Teva Pharmaceutical Industries Stock Forecast, Price & News

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Teva Pharmaceutical Industries in the last twelve months. There are currently 1 sell rating, 7 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Teva Pharmaceutical Industries stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TEVA, but not buy additional shares or sell existing shares.
View analyst ratings for Teva Pharmaceutical Industries or view top-rated stocks.

Wall Street analysts have given Teva Pharmaceutical Industries a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Teva Pharmaceutical Industries wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Teva Pharmaceutical Industries is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Teva Pharmaceutical Industries.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) issued its quarterly earnings data on Wednesday, July, 28th. The company reported $0.59 EPS for the quarter, topping the consensus estimate of $0.55 by $0.04. Teva Pharmaceutical Industries had a negative net margin of 23.98% and a positive trailing twelve-month return on equity of 23.88%.
View Teva Pharmaceutical Industries' earnings history.

Teva Pharmaceutical Industries' stock was trading at $9.01 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, TEVA shares have increased by 10.1% and is now trading at $9.92.
View which stocks have been most impacted by COVID-19.

Teva Pharmaceutical Industries updated its FY 2021 earnings guidance on Wednesday, August, 4th. The company provided EPS guidance of $2.500-$2.700 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.450. The company issued revenue guidance of $16 billion-$16.40 billion, compared to the consensus revenue estimate of $16.55 billion.

10 brokers have issued 12 month target prices for Teva Pharmaceutical Industries' shares. Their forecasts range from $8.00 to $14.00. On average, they anticipate Teva Pharmaceutical Industries' share price to reach $11.44 in the next twelve months. This suggests a possible upside of 15.4% from the stock's current price.
View analysts' price targets for Teva Pharmaceutical Industries or view top-rated stocks among Wall Street analysts.

158 employees have rated Teva Pharmaceutical Industries CEO Kåre Schultz on Glassdoor.com. Kåre Schultz has an approval rating of 90% among Teva Pharmaceutical Industries' employees.

Some companies that are related to Teva Pharmaceutical Industries include Alexion Pharmaceuticals (ALXN), BeiGene (BGNE), Astellas Pharma (ALPMY), Genmab A/S (GNMSF), Genmab A/S (GMAB), MERCK Kommanditgesellschaft auf Aktien (MKGAF), Shiseido (SSDOY), Takeda Pharmaceutical (TKPYY), Royalty Pharma (RPRX), Horizon Therapeutics Public (HZNP), Alnylam Pharmaceuticals (ALNY), Catalent (CTLT), UCB (UCBJF), Elanco Animal Health (ELAN) and Viatris (VTRS).
View all of TEVA's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Teva Pharmaceutical Industries investors own include General Electric (GE), AT&T (T), NVIDIA (NVDA), Alibaba Group (BABA), Intel (INTC), Bank of America (BAC), Micron Technology (MU), Gilead Sciences (GILD), Johnson & Johnson (JNJ) and Cisco Systems (CSCO).

Teva Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TEVA."

Teva Pharmaceutical Industries' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Harel Insurance Investments & Financial Services Ltd. (0.91%), Beck Mack & Oliver LLC (0.41%), Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management (0.33%), Sumitomo Mitsui Trust Holdings Inc. (0.26%), Private Management Group Inc. (0.19%) and Asset Management One Co. Ltd. (0.05%). Company insiders that own Teva Pharmaceutical Industries stock include Brendan P O'grady, David Matthew Stark, Deborah A Griffin, Eric Drape, Hafrun Fridriksdottir, Luzich Partners Llc, Mark Sabag, Michael James Mcclellan, Pharmaceutical Co Ltd Takeda, Richard Daniell and Rosemary A Crane.
View institutional ownership trends for Teva Pharmaceutical Industries.

TEVA stock was sold by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Victory Capital Management Inc., Harel Insurance Investments & Financial Services Ltd., Focused Wealth Management Inc, Signature Wealth Management Partners LLC, Oppenheimer & Co. Inc., Alliancebernstein L.P., and Capital Wealth Planning LLC. Company insiders that have sold Teva Pharmaceutical Industries company stock in the last year include David Matthew Stark, Eric Drape, Mark Sabag, Pharmaceutical Co Ltd Takeda, Richard Daniell, and Rosemary A Crane.
View insider buying and selling activity for Teva Pharmaceutical Industries or view top insider-selling stocks.

TEVA stock was purchased by a variety of institutional investors in the last quarter, including Beck Mack & Oliver LLC, Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management, Private Management Group Inc., Financial Sense Advisors Inc., Davy Global Fund Management Ltd, Advisor Group Holdings Inc., Baldwin Brothers Inc. MA, and New York State Common Retirement Fund.
View insider buying and selling activity for Teva Pharmaceutical Industries or or view top insider-buying stocks.

Shares of TEVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of TEVA stock can currently be purchased for approximately $9.92.

Teva Pharmaceutical Industries has a market capitalization of $10.83 billion and generates $16.66 billion in revenue each year. The company earns $-3,990,000,000.00 in net income (profit) each year or $2.45 on an earnings per share basis.

Teva Pharmaceutical Industries employs 40,216 workers across the globe.

The official website for Teva Pharmaceutical Industries is www.tevapharm.com.

Teva Pharmaceutical Industries is headquartered at 5 BAZEL ST P O B 3190, PETACH TIKVA L3, 49131.

Teva Pharmaceutical Industries' mailing address is 5 BAZEL ST P O B 3190, PETACH TIKVA L3, 49131. The company can be reached via phone at 972-3914-8171 or via email at [email protected]